Page 7 - Bharat Biotech

Bharat Biotech seeks nod for phase-3 clinical trials of nasal vaccine

The Hyderabad-based vaccine maker conducted phase 2 trials on 650 volunteers

Covid-19 vaccine Covaxin's shelf life extended to 12 months: Bharat Biotech

The multi-dose vial policy saves money for procurement agencies by reducing the cold chain logistics

Bharat Biotech seeks trial for intranasal Covid vaccine booster

'We have submitted phase 3 clinical trial application to DCGI (Drugs Controller General of India)," a Bharat Biotech spokesperson said

Covaxin for 2-18 yrs: Examining Expert Committee recommendations, says govt

Union Minister of State for Health Bharati Pravin Pawar shared the information through a written reply in Rajya Sabha

Bharat Biotech resumes Covaxin export with 'long-pending orders' in Nov

The Centre allowed commercial exports of Covaxin last week

'Long pending orders executed': Bharat Biotech resumes exports of Covaxin

India restarted on Friday exports of Covid-19 shots to COVAX for the first time since April

Bharat Biotech updates Covaxin efficacy to 65.2% against Delta variant

Experts say more real-world studies are required now

Centre allows Bharat Biotech to begin commercial exports of Covaxin

Bharat Biotech made 55 million doses of Covaxin in October, and aims to make 80 million doses in December.

Covaxin doses 50% effective against symptomatic Covid: Real-world study

Research does not estimate vaccine effectiveness against hospitalisation, severe disease, and death.

India-made Covid-19 vaccine Covaxin now on UK's approved travel list

Earlier this month, the Bharat Biotech manufactured Covaxin had received its WHO EUL status

Vaccine makers ramp up production capacities despite low current demand

Booster shot, children vaccination, exports can spike demand in the future

Developing Covaxin was an enormous challenge: Bharat Biotech

Bharat Biotech Director V Krishna Mohan said said there were no vaccines when Covid-19 hit India, and the world

Bharat Biotech's Covid-19 vaccine Covaxin gets mixed review from Lancet

Extrapolating from the report, Lancet said 'two doses offer 77.8 per cent protection against symptomatic Covid-19'.

Covid booster dose required if virus gets mutated: Bharat Biotech MD

India has done an amazing job, Dr Ella said on India surpassing the administration of 100 Crore vaccination

6 months post second dose ideal for booster: Bharat Biotech's Krishna Ella

The ideal time for a booster dose for COVID-19 vaccine is six months after the second dose, Bharat Biotech Chairman and Managing Director Krishna Ella said

Top headlines: Paytm IPO subscribed 1.89 times; Nykaa makes stellar debut

Business Standard brings you the top stories from today

SC to hear plea seeking disclosure of data on Covid shots' trials on Nov 29

The apex court had earlier in August asked the Centre, Bharat Biotech, SII, and others to respond to the plea which sought directions to also disclose post-vaccination data regarding adverse events

Covaxin for children will take some more time for final approval: Report

Recently, the Subject Expert Committee had given a recommendation to the DCGI for the use of Bharat Biotech's Covaxin Covid-19 vaccine for the beneficiaries aged between 2-18 years

LIVE: Merck's Covid pill secures green light from UK regulator

Live news updates: Bharat Biotech's home-grown Covid-19 vaccine now many be used for Covid-19 inoculation in poor countries.

Bharat Biotech's Covaxin set to go global after WHO gives it a booster

Becomes sixth vaccine to receive validation; move will ease foreign travel for those who got jab